Sanofi India Board Approves Q2 2026 Unaudited Results, Reconstitutes Committees
Sanofi India Ltd's Board of Directors met on August 4, 2026, to approve the unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported strong Q2 2026 performance with domestic net sales up 8% and total net sales up 6% year-on-year. The Diabetes Portfolio, particularly Insulin, showed double-digit growth of 14%. Profits before tax and exceptional items increased by 19% to INR 112 crores, with profit margin improving to 27%. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, effective October 1, 2026. Additionally, Mr. Rachid Ayari will step down as Whole Time Director and CFO on September 30, 2026.
Key Highlights
- Q2 2026 unaudited financial results approved.
- Net sales grew 6% YoY; Diabetes portfolio up 14%.
- Profit before tax increased 19% to INR 112 crores.
- Key committees reconstituted; CFO stepping down.
- Strong performance driven by diabetes and cost management.
Price Impact
More from SANOFI